<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083250</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0999</org_study_id>
    <secondary_id>NCI-2014-01982</secondary_id>
    <secondary_id>2012-0999</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02083250</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of vorinostat when given together
      with fludarabine phosphate, clofarabine, and busulfan in treating patients with acute
      leukemia that is under control (remission) or has returned (relapse) undergoing donor stem
      cell transplant. Vorinostat may stop the growth of cancer cells by blocking some of the
      enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate,
      clofarabine, and busulfan, work in different ways to stop the growth of cancer cells, either
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      Giving vorinostat together with fludarabine phosphate, clofarabine, and busulfan before a
      donor stem cell transplant may be a better treatment for patients with acute leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) of SAHA (vorinostat) in combination with the
      preparative regimen fludarabine (fludarabine phosphate), clofarabine, and busulfan followed
      by allogeneic hematopoietic stem cell transplantation (SCT) for patients with advanced acute
      leukemia.

      SECONDARY OBJECTIVES:

      I. To determine the rate of graft versus host disease (GVHD), engraftment, progression-free
      survival (PFS) and overall survival (OS) for this treatment regimen.

      OUTLINE: This is a dose-escalation study of vorinostat.

      CONDITIONING REGIMEN: Patients receive vorinostat orally (PO) once daily (QD), fludarabine
      phosphate intravenously (IV) over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3
      hours on days -6 to -3. Patients receiving a transplant from a human leukocyte antigen
      (HLA)-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to
      -1.

      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant
      on day 0.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2014</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using Common Terminology Criteria for Adverse Events version 4</measure>
    <time_frame>30 days</time_frame>
    <description>The 2-stage time-to-event continual reassessment method will be used. Toxicity will be tabulated by dose, type, and grade. The probability of toxicity over 30 days as a function of dose will be estimated by fitting a Bayesian binary outcome regression model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated by the Kaplan and Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated by the Kaplan and Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation Recipient</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.
TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>MSK-390</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberanilohydroxamic Acid</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy-proven acute lymphoblastic leukemia, acute myeloid leukemia, or
             myelodysplastic syndrome in remission or relapse

          -  Estimated creatinine clearance at least 50 ml/min

          -  Bilirubin equal or less than 1.5 (unless Gilbert's syndrome)

          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 3 x upper limit of normal

          -  Alkaline phosphatase &lt; 2 x upper limit of normal

          -  Pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital
             capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at least
             45% of expected corrected for hemoglobin; children unable to perform pulmonary
             functions must have an oxygen saturation greater than 92% at room air

          -  Left ventricular ejection fraction at least 45% on appropriate medical therapy; no
             uncontrolled arrhythmias or symptomatic cardiac disease

          -  Zubrod performance status 0-1 or Lansky/Karnofsky performance status (PS) equal or
             greater to 80%

          -  Patients must have a related, genotypically HLA identical donor, or they must have an
             unrelated donor who is 8/8 HLA match by high resolution typing

          -  Patient or patient's legal representative, parent(s) or guardian should provide
             written informed consent; assent of a minor if participant's age is at least seven and
             less than eighteen years

          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months and no previous surgical
             sterilization

        Exclusion Criteria:

          -  Patients with active central nervous system (CNS) disease

          -  Evidence of acute or chronic active hepatitis or cirrhosis

          -  Uncontrolled infection, including human immunodeficiency virus (HIV), human
             T-lymphotropic virus (HTLV)-1, hepatitis B or hepatitis C viremia

          -  Prior allogeneic SCT

          -  Prior autologous SCT in last 12 months

          -  Patients with acute myeloid leukemia (AML) in first remission after one course of
             induction and with favorable cytogenetics (t[8;21], inv 16, or t[15;17]) and/or
             molecular profile (nucleophosmin [NPM]1)

          -  Prior radiation to liver in form of total body or involved field
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

